Related Experiment Video
Updated: Jun 25, 2026
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management
Terence C Chua1, Tristan D Yan, David L Morris
1University of New South Wales, Department of Surgery, St. George Hospital, Kogarah, New South Wales, Sydney, Australia.
Abstract:
Mesothelioma is an asbestos-related tumour. Mesothelioma in the thorax occurs on the pleura and is known as pleural mesothelioma. It is the more common form of mesothelioma, accounting for 70% of cases. The other form occurs in the abdomen. It accounts for much of the remaining 30% and is known as peritoneal mesothelioma. Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract. Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity. Treatment approaches have evolved in the last decade from systemic chemotherapy and palliative surgery to aggressive cytoreductive surgery and perioperative intraperitoneal chemotherapy. This has led to a marked increase in survival among patients who were once classified as "preterminal." We update on the current understanding of peritoneal mesothelioma from a clinical perspective in hope that greater clinician awareness will promote best practice management of this condition.
Insights
Peritoneal mesothelioma, an asbestos-related cancer, is often diagnosed late due to subtle symptoms. Advanced surgical and chemotherapy techniques are improving survival rates for patients with this rare cancer.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Mesothelioma is a rare cancer linked to asbestos exposure.
- Pleural mesothelioma affects the chest (70% of cases), while peritoneal mesothelioma affects the abdomen (30%).
- Peritoneal mesothelioma diagnosis is challenging due to non-specific early symptoms mimicking gastrointestinal issues, often leading to late-stage detection.
Purpose of the Study:
- To provide an updated clinical overview of peritoneal mesothelioma.
- To enhance clinician awareness for improved patient management.
- To highlight advancements in treatment strategies.
Main Methods:
- Review of current clinical understanding and treatment approaches for peritoneal mesothelioma.
- Analysis of treatment evolution from palliative care to aggressive cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Main Results:
- Treatment advancements have significantly improved survival for patients with peritoneal mesothelioma.
- Aggressive cytoreductive surgery combined with perioperative intraperitoneal chemotherapy offers improved outcomes.
- Earlier diagnosis remains a significant challenge.
Conclusions:
- Increased clinician awareness is crucial for timely diagnosis and optimal management of peritoneal mesothelioma.
- Modern multimodal treatment strategies offer hope for patients.
- Further research into early detection methods is warranted.
